Literature DB >> 20066118

Tumor suppressive functions of p53.

Jack T Zilfou1, Scott W Lowe.   

Abstract

The majority of human cancers acquire mutations that abrogate the p53 tumor suppressor network and, as a consequence, p53 is one of the most extensively studied proteins in cancer research. Because of its potent tumor suppressive activity, it is widely assumed that a molecular understanding of p53 action will produce fundamental insights into natural processes that limit tumorigenesis and may identify key molecular targets for therapeutic intervention. p53 functions largely as a transcription factor, and can trigger a variety of antiproliferative programs by activating or repressing key effector genes. Despite a significant body of literature detailing the biochemical and biological functions of p53, much remains to be elucidated. Indeed, the p53 network is as complex and enigmatic as it is relevant. It is the goal of this article, written 30 years after the discovery of p53, to present a concise review of the tumor suppressor role of the p53 network and to highlight the context-dependent nature of p53 target-gene functions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20066118      PMCID: PMC2773645          DOI: 10.1101/cshperspect.a001883

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  71 in total

1.  The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.

Authors:  J T Zilfou; W H Hoffman; M Sank; D L George; M Murphy
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 2.  Drug-induced liver disorders: implications for drug development and regulation.

Authors:  N Kaplowitz
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

4.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

5.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.

Authors:  J Parant; A Chavez-Reyes; N A Little; W Yan; V Reinke; A G Jochemsen; G Lozano
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

6.  Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts.

Authors:  J P Brown; W Wei; J M Sedivy
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

7.  A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.

Authors:  Clemens A Schmitt; Jordan S Fridman; Meng Yang; Soyoung Lee; Eugene Baranov; Robert M Hoffman; Scott W Lowe
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

8.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.

Authors:  R Montes de Oca Luna; D S Wagner; G Lozano
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

9.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.

Authors:  X Chen; L J Ko; L Jayaraman; C Prives
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

Review 10.  p300/CBP proteins: HATs for transcriptional bridges and scaffolds.

Authors:  H M Chan; N B La Thangue
Journal:  J Cell Sci       Date:  2001-07       Impact factor: 5.285

View more
  194 in total

1.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  PIASy-mediated Tip60 sumoylation regulates p53-induced autophagy.

Authors:  Samisubbu R Naidu; Alexander J Lakhter; Elliot J Androphy
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

Review 3.  p53 at a glance.

Authors:  Colleen A Brady; Laura D Attardi
Journal:  J Cell Sci       Date:  2010-08-01       Impact factor: 5.285

4.  Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Cε.

Authors:  Moammir H Aziz; Hong Shen; Carl G Maki
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

5.  The multifunctional sorting protein PACS-2 regulates SIRT1-mediated deacetylation of p53 to modulate p21-dependent cell-cycle arrest.

Authors:  Katelyn M Atkins; Laura L Thomas; Jonathan Barroso-González; Laurel Thomas; Sylvain Auclair; Jun Yin; Hyeog Kang; Jay H Chung; Jimmy D Dikeakos; Gary Thomas
Journal:  Cell Rep       Date:  2014-08-21       Impact factor: 9.423

Review 6.  Expanding molecular roles of UV-DDB: Shining light on genome stability and cancer.

Authors:  Maria Beecher; Namrata Kumar; Sunbok Jang; Vesna Rapić-Otrin; Bennett Van Houten
Journal:  DNA Repair (Amst)       Date:  2020-04-27

7.  Pathways of Metabolite-Related Damage to a Synthetic p53 Gene Exon 7 Oligonucleotide Using Magnetic Enzyme Bioreactor Beads and LC-MS/MS Sequencing.

Authors:  Spundana Malla; Karteek Kadimisetty; Di Jiang; Dharamainder Choudhary; James F Rusling
Journal:  Biochemistry       Date:  2018-05-23       Impact factor: 3.162

8.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

Review 9.  Long story short: p53 mediates innate immunity.

Authors:  Jessica Miciak; Fred Bunz
Journal:  Biochim Biophys Acta       Date:  2016-03-04

Review 10.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.